

WOMEN AND LUNG CANCER RESEARCH AND
PREVENTIVE SERVICES ACT OF 2024

JULY 30, 2024.—Committed to the Committee of the Whole House on the State of
the Union and ordered to be printed

Mrs. RODGERS of Washington, from the Committee on Energy and
Commerce, submitted the following

R E P O R T

[To accompany H.R. 4534]

The Committee on Energy and Commerce, to whom was referred
the bill (H.R. 4534) to require a review of women and lung cancer,
and for other purposes, having considered the same, reports favor-
ably thereon with an amendment and recommends that the bill as
amended do pass.

CONTENTS

	Page
Purpose and Summary	2
Background and Need for Legislation	2
Committee Action	3
Committee Votes	3
Oversight Findings and Recommendations	5
New Budget Authority, Entitlement Authority, and Tax Expenditures	5
Congressional Budget Office Estimate	5
Federal Mandates Statement	5
Statement of General Performance Goals and Objectives	5
Duplication of Federal Programs	5
Related Committee and Subcommittee Hearings	5
Committee Cost Estimate	6
Earmark, Limited Tax Benefits, and Limited Tariff Benefits	6
Advisory Committee Statement	6
Applicability to Legislative Branch	6
Section-by-Section Analysis of the Legislation	6
Changes in Existing Law Made by the Bill, as Reported	7

The amendment is as follows:

Strike all after the enacting clause and insert the following:

SECTION 1. SHORT TITLE.

This Act may be cited as the “Women and Lung Cancer Research and Preventive
Services Act of 2024”.

SEC. 2. INTERAGENCY REVIEW TO EVALUATE AND IDENTIFY OPPORTUNITIES FOR THE ACCELERATION OF RESEARCH ON LUNG CANCER IN WOMEN AND UNDERSERVED POPULATIONS, GREATER ACCESS TO PREVENTIVE SERVICES, AND STRATEGIC PUBLIC AWARENESS AND EDUCATION CAMPAIGNS.

(a) **IN GENERAL.**—The Secretary of Health and Human Services, in consultation with the Secretary of Defense and Secretary of Veterans Affairs, shall conduct an interagency review to evaluate the status of, and identify opportunities related to—

- (1) research on lung cancer in women;
- (2) research on lung cancer in underserved populations that meet the eligibility criteria for lung cancer screening as recommended by the United States Preventive Services Task Force;
- (3) access to lung cancer preventive services; and
- (4) strategic public awareness and education campaigns on lung cancer.

(b) **CONTENT.**—The review and recommendations under subsection (a) shall include—

- (1) a review and comprehensive report on the outcomes of previous research, the status of existing research activities, and knowledge gaps related to lung cancer in women and underserved populations in all agencies of the Federal Government;
- (2) opportunities for collaborative, interagency, multidisciplinary, and innovative research, that would—
 - (A) encourage innovative approaches to eliminate knowledge gaps in research on lung cancer in women;
 - (B) evaluate environmental and genomic factors that may be related to the etiology of lung cancer in women; and
 - (C) foster advances in imaging technology and techniques to improve risk assessment, diagnosis, treatment, and the simultaneous utilization of other preventive services and activities;
- (3) opportunities regarding the development of a national lung cancer screening strategy to expand access to such screenings, particularly among women and underserved populations; and
- (4) opportunities regarding the development of a national public education and awareness campaign on—
 - (A) lung cancer in women and underserved populations; and
 - (B) the importance of early detection of lung cancer.

(c) **REPORT.**—Not later than two years after the date of the enactment of this Act, the Secretary of Health and Human Services shall submit to Congress a report on the review conducted under subsection (a).

PURPOSE AND SUMMARY

H.R. 4534 requires The Department of Health and Human Services (HHS) to conduct an interagency review on the status of, and identify research related to, women and underserved populations with lung cancer. The review would include assessments of current research and access to prevention services, the availability of research opportunities regarding prevention, detection, and treatment, and recommendations for national public education and screening strategies.

BACKGROUND AND NEED FOR LEGISLATION

Lung cancer is the third most common cancer in the United States.¹ Worldwide, over 600,000 women die of lung cancer each year.² About 10 to 20 percent of lung cancers, or 20,000 to 40,000 lung cancers each year, happen in people who never smoked or smoked fewer than 100 cigarettes in their lifetime.³ A better under-

¹“Lung Cancer Statistics,” *U.S. Centers for Disease Control and Prevention*, June 13, 2024, https://www.cdc.gov/lung-cancer/statistics/?CDC_AAref_Val=https://www.cdc.gov/cancer/lung/statistics/index.htm.

²“Women and Lung Cancer,” *Lung Cancer Research Foundation*, <https://www.lungcancerresearchfoundation.org/for-patients/women-and-lc/>.

³“Lung Cancer Among People Who Never Smoked,” *U.S. Centers for Disease Control and Prevention*, December 4, 2023, <https://www.cdc.gov/lung-cancer/nonsmokers/index.html#:~:text=cancer%2C%20and%20asbestos.,In%20the%20United%20States%2C%20about%2010%25%20to%2020%25%20of,2%2C900%20of%20these%20lung%20cancers.>

standing of additional risk factors beyond smoking cigarettes is needed for more effective screening, diagnosis, and treatment.

H.R. 4534 would review and assess current research on lung cancer in women and certain underserved populations, as well as evaluate current relevant opportunities related to education and access to prevention, detection, and treatment services.

COMMITTEE ACTION

On February 14, 2024, the Subcommittee on Health held a hearing on H.R. 4534. The title of the hearing was “Legislative Proposals to Support Patients and Caregivers.” The Subcommittee received testimony from:

- Andy Shih, PhD, Chief Science Officer, Autism Speaks;
- Corey Feist, JD, MBA, Co-Founder and CEO, Dr. Lorna Breen Heroes’ Foundation;
- Joanne Pike, DrPH, President and CEO, Alzheimer’s Association;
- Gordon Tomaselli, MD, Former President, American Heart Association; Marilyn and Stanley M. Katz Dean, Emeritus and Professor of Medicine, Albert Einstein College of Medicine; Adjunct Professor of Medicine, Johns Hopkins University School of Medicine;
- Michelle Whitten, President, CEO, and Co-Founder, Global Down Syndrome Foundation;
- Randy Strozyk, President, American Ambulance Association; and,
- Christina Annunziata, MD, PhD, Senior Vice President of Extramural Discovery Science, American Cancer Society.

On May 16, 2024, the Subcommittee on Health met in open markup session and forwarded H.R. 4534, as amended, to the full Committee by a record vote of 21 yeas to 0 nays.

On June 12, 2024, the full Committee on Energy and Commerce met in open markup session and ordered H.R. 4534, as amended, favorably reported to the House by a record vote of 44 yeas and 0 nays.

COMMITTEE VOTES

Clause 3(b) of rule XIII requires the Committee to list the record votes on the motion to report legislation and amendments thereto. The following reflects the record votes taken during the Committee consideration:

**COMMITTEE ON ENERGY AND COMMERCE
118TH CONGRESS
ROLL CALL VOTE # 3**

BILL: H.R. 4534, Women and Lung Cancer Research and Preventative Services Act of 2023

AMENDMENT: A motion by Chair Rodgers to order H.R. 4534 favorably reported to the House, as amended (Final Passage).

DISPOSITION: AGREED TO, by a recorded vote of 44 Yeas to 0 Nays.

REPRESENTATIVE	YEAS	NAYS	PRESENT	REPRESENTATIVE	YEAS	NAYS	PRESENT
Rep. Rodgers	X			Rep. Pallone	X		
Rep. Burgess	X			Rep. Eshoo	X		
Rep. Latta	X			Rep. DeGette	X		
Rep. Guthrie	X			Rep. Schakowsky	X		
Rep. Griffith	X			Rep. Matsui	X		
Rep. Bilirakis	X			Rep. Castor	X		
Rep. Bucshon	X			Rep. Sarbanes	X		
Rep. Hudson				Rep. Tonko	X		
Rep. Walberg				Rep. Clarke	X		
Rep. Carter	X			Rep. Cárdenas	X		
Rep. Duncan	X			Rep. Ruiz	X		
Rep. Palmer	X			Rep. Peters	X		
Rep. Dunn				Rep. Dingell	X		
Rep. Curtis				Rep. Veasey	X		
Rep. Lesko	X			Rep. Kuster	X		
Rep. Pence	X			Rep. Kelly	X		
Rep. Crenshaw				Rep. Barragán	X		
Rep. Joyce	X			Rep. Blunt Rochester			
Rep. Armstrong				Rep. Soto	X		
Rep. Weber	X			Rep. Craig	X		
Rep. Allen	X			Rep. Schrier	X		
Rep. Balderson	X			Rep. Trahan	X		
Rep. Fulcher	X			Rep. Fletcher	X		
Rep. Pfluger							
Rep. Harshbarger	X						
Rep. Miller-Meeks	X						
Rep. Cammack	X						
Rep. Obernolte	X						
Rep. James	X						

06/12/2024

OVERSIGHT FINDINGS AND RECOMMENDATIONS

Pursuant to clause 2(b)(1) of rule X and clause 3(c)(1) of rule XIII, the Committee held a hearing and made findings that are reflected in this report.

NEW BUDGET AUTHORITY, ENTITLEMENT AUTHORITY, AND TAX EXPENDITURES

Pursuant to clause 3(c)(2) of rule XIII, the Committee finds that H.R. 4534 would result in no new or increased budget authority, entitlement authority, or tax expenditures or revenues.

CONGRESSIONAL BUDGET OFFICE ESTIMATE

Pursuant to clause 3(c)(3) of rule XIII, at the time this report was filed, the cost estimate prepared by the Director of the Congressional Budget Office pursuant to section 402 of the Congressional Budget Act of 1974 was not available.

FEDERAL MANDATES STATEMENT

The Committee adopts as its own the estimate of Federal mandates prepared by the Director of the Congressional Budget Office pursuant to section 423 of the Unfunded Mandates Reform Act.

STATEMENT OF GENERAL PERFORMANCE GOALS AND OBJECTIVES

Pursuant to clause 3(c)(4) of rule XIII, the general performance goal or objective of this legislation is to review, evaluate the status of, and identify research and educational opportunities related to lung cancer in women and certain underserved populations.

DUPLICATION OF FEDERAL PROGRAMS

Pursuant to clause 3(c)(5) of rule XIII, no provision of H.R. 4534 is known to be duplicative of another Federal program, including any program that was included in a report to Congress pursuant to section 21 of Public Law 111–139 or the most recent Catalog of Federal Domestic Assistance.

RELATED COMMITTEE AND SUBCOMMITTEE HEARINGS

Pursuant to clause 3(c)(6) of rule XIII, the following related hearing was used to develop or consider H.R. 4534:

- On February 14, 2024, the Subcommittee on Health held a hearing on H.R. 4534. The title of the hearing was “Legislative Proposals to Support Patients and Caregivers.” The Subcommittee received testimony from:
 - Andy Shih, PhD, Chief Science Officer, Autism Speaks;
 - Corey Feist, JD, MBA, Co-Founder and CEO, Dr. Lorna Breen Heroes’ Foundation;
 - Joanne Pike, DrPH, President and CEO, Alzheimer’s Association;
 - Gordon Tomaselli, MD, Former President, American Heart Association; Marilyn and Stanley M. Katz Dean, Emeritus and Professor of Medicine, Albert Einstein College of Medicine; Adjunct Professor of Medicine, Johns Hopkins University School of Medicine;

- Michelle Whitten, President, CEO, and Co-Founder, Global Down Syndrome Foundation;
- Randy Strozyk, President, American Ambulance Association; and,
- Christina Annunziata, MD, PhD, Senior Vice President of Extramural Discovery Science, American Cancer Society.

COMMITTEE COST ESTIMATE

Pursuant to clause 3(d)(1) of rule XIII, the Committee adopts as its own the cost estimate prepared by the Director of the Congressional Budget Office pursuant to section 402 of the Congressional Budget Act of 1974. At the time this report was filed, the estimate was not available.

EARMARK, LIMITED TAX BENEFITS, AND LIMITED TARIFF BENEFITS

Pursuant to clause 9(e), 9(f), and 9(g) of rule XXI, the Committee finds that H.R. 4534 contains no earmarks, limited tax benefits, or limited tariff benefits.

ADVISORY COMMITTEE STATEMENT

No advisory committees within the meaning of section 5(b) of the Federal Advisory Committee Act were created by this legislation.

APPLICABILITY TO LEGISLATIVE BRANCH

The Committee finds that the legislation does not relate to the terms and conditions of employment or access to public services or accommodations within the meaning of section 102(b)(3) of the Congressional Accountability Act.

SECTION-BY-SECTION ANALYSIS OF THE LEGISLATION

Section 1. Short title

Section 1 provides that the Act may be cited as the “Women and Lung Cancer Research and Preventative Services Act of 2024”.

Section 2. Interagency review to evaluate and identify opportunities for the acceleration of research on lung cancer in women and underserved populations, greater access to preventative services, and strategic public awareness and education campaigns

Section 2 requires the Department of Health and Human Services (HHS) to conduct an interagency review on the status of, and identify research and education opportunities related to, women and certain underserved populations with lung cancer. The review would include assessments of current research and access to prevention services, the availability of research opportunities regarding prevention, detection, and treatment, and recommendations for national public education and screening strategies. This section also requires the HHS Secretary to submit a report to Congress detailing the results of the review within two years of enactment.

CHANGES IN EXISTING LAW MADE BY THE BILL, AS REPORTED
This legislation does not amend any existing Federal statute.

